Your browser doesn't support javascript.
loading
The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study.
Talks, S James; Daien, Vincent; Mitchell, Paul; Aslam, Tariq; Barratt, Jane; Biberger, Anna; Lamoureux, Ecosse L; Hirst, Ceri; Sylvanowicz, Michelle; Finger, Robert P.
Afiliación
  • Talks SJ; Newcastle Eye Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. james.talks@nhs.net.
  • Daien V; Department of Ophthalmology, University Hospital of Montpellier, Montpellier, France.
  • Mitchell P; University of Sydney (Westmead Institute for Medical Research), Sydney, NSW, Australia.
  • Aslam T; Manchester Royal Eye Hospital, Manchester, UK.
  • Barratt J; University of Manchester, Manchester, UK.
  • Biberger A; International Federation on Ageing, Toronto, ON, Canada.
  • Lamoureux EL; Cerner Enviza, Munich, Germany.
  • Hirst C; Singapore Eye Research Institute, Singapore, Singapore.
  • Sylvanowicz M; Duke-NUS Medical School, Singapore, Singapore.
  • Finger RP; Bayer Consumer Care AG, Basel, Switzerland.
Ophthalmol Ther ; 12(1): 561-575, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36525220
Neovascular age-related macular degeneration (nAMD), also known as wet age-related macular degeneration (wAMD), is an eye condition that is a common cause of vision loss and worsens over time without treatment. This condition mainly occurs in people aged 70 years or older. The standard of care is an injection of anti-vascular endothelial growth factor (anti-VEGF) into the eye to minimise vision loss that continues over time without treatment. To maximise the benefits of treatment, injections are required at regular intervals over time. The purpose of this study was to understand the emotions and experiences of patients with nAMD about their disease, its consequences, and its management. Seventeen patients from three countries (France, Germany, and the UK) were interviewed over the telephone. Patients reported diverse feelings and responses to their disease and treatment. Many felt nervous and anxious at diagnosis and before their first injection (despite reassurances from their doctors); however, after the first injection, these feelings and apprehension abated for many, but not all. Most patients (76%) missed fewer than two appointments in the past year, and almost all (82%) did not consider stopping treatment. Patients learned to deal with their nAMD, but many had difficulties with daily activities. Patients developed ways to manage tasks such as cooking, cleaning, knitting, and driving. The insights from this study help understand how care for patients with nAMD can be improved by addressing patients' concerns and feelings about their disease and treatment.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Qualitative_research Aspecto: Patient_preference Idioma: En Revista: Ophthalmol Ther Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Qualitative_research Aspecto: Patient_preference Idioma: En Revista: Ophthalmol Ther Año: 2023 Tipo del documento: Article
...